Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Group sales revenue rose 7.6%
Earnings (EBIT) up 19.2%
EBIT margin target of 10% reached / Earnings per share surged 31.2% from EUR1.30 to EUR1.70
Accelerated growth and further profitabi

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

25.01.2007

In fiscal 2006, group sales revenue rose 7.6% (currency-adjusted: +8.1%) to EUR521.1 million (2005: EUR484.3 mn). Due to double-digit growth rates in the filter business, the Biotechnology Division posted an increase in sales revenue of 8.5% (currency-adjusted: +9.0%) to EUR271.0 million (2005: EUR249.8 mn). Sales revenue for the Mechatronics Division climbed 6.6% (currency-adjusted: +7.1%) to EUR250.0 million (2005: 234.5 mn). During the same period, Group order intake grew 5.4% (currency-adjusted: +5.9%) to EUR523.9 million (2005: EUR497.0 mn).

Earnings before interest, taxes, depreciation and amortization (EBITDA) jumped from EUR62.1 million to EUR71.2 million (+14.6%); EBIT surged 19.2% to EUR52.1 million (2005: EUR43.7 mn). For the Biotechnology Division, EBIT soared from EUR24.3 million to EUR31.8 million (+31.0%); for the Mechatronics Division, from EUR19.4 million to EUR20.2 million (+4.5%). The Group EBIT margin improved in line with our target from 9.0% to 10.0%. Consolidated net profit shot up 31.2% to EUR29.0 million (2005: 22.1 mn); accordingly, earnings per share climbed from EUR1.30 to EUR1.70.

Although capital expenditures more than doubled according to the budget, net cash flow at EUR20.5 million (2005: EUR32.1 mn) remained significantly positive again. Net debt was reduced by EUR6.3 million to EUR54.4 million.

For fiscal 2007, we are striving to further accelerate growth and assume that on the basis of constant currencies, sales revenue will rise by about 10%. We intend to boost EBIT to approx. 11% of consolidated sales revenue. Our new five-year plan forecasts a further increase in EBIT margin based on average annual sales growth of around 10%.

The figures stated above are still subject to the auditors’ final review. The final numbers will be published at the annual press conference on March 13, 2007.

@@start.t2@@end of announcement                                                 euro adhoc 25.01.2007 07:30:28
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Phone: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Niedersächsische Börse zu Hannover / official dealing



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: